Picard Medical

PMI

Market cap $14.6M

TUCSON, Ariz., May 05, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the pricing of its "reasonable best efforts" offering with certain new and existing institutional investors for the purchase and sale of (i) 16,666,667 shares of the Company's common stock, par value $0.0001 per share (or common stock equivalents in lieu thereof) (the “Common Stock”), (ii) series A common warrants to purchase up to 16,666,667 shares of Common Stock (the “Series A Common Warrants”), and (iii) series B common warrants to purchase up to 16,666,667 shares of Common Stock (the “Series B Common Warrants” together with the Series A Common Warrants, the “Common Warrants”) (the “Offering”).

Banner Health has performed more than 50 SynCardia Total Artificial Heart implants, establishing itself as a leading center in total artificial heart therapy Banner Health has performed more than 50 SynCardia Total Artificial Heart implants, establishing itself as a leading center in total artificial heart therapy

– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development – TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, announced today it has been featured in a two-part interview series with Joe Mullings, Chairman and Chief Executive Officer of The Mullings Group Companies, a premier global executive search firm specialized in the MedTech, HealthTech, and Life Sciences industries.

Health care was the most significant detractor, led by weakness within life sciences tools and services, while consumer discretionary and IT also weighed on relative performance. Regal Rexnord Corp. performed strongly in the first quarter, primarily on account of a quarterly report that featured particularly strong orders owing to budding demand for data center products. Westlake Corp. outperformed in the first quarter due to the effects on global chemical markets from the conflict in Iran, which has had an extreme impact on supply.

TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced its participation in the International Society for Heart and Lung Transplantation (“ISHLT”) 2026 Annual Meeting, to be held at the Metro Toronto Convention Centre in Toronto, Canada.

NEW YORK--(BUSINESS WIRE)---- $PMI #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Picard Medical, Inc. (“Picard” or the “Company”) (NYSE: PMI) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm ha.

LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Picard Medical, Inc. (“Picard” or “the Company”) (NYSE American: PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 2, 2025 and October 31, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 13, 2026.

LOS ANGELES, April 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Picard Medical, Inc. ("Picard" or "the Company") (NYSE American: PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

LOS ANGELES, April 12, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Picard Medical, Inc. ("Picard" or "the Company") (NYSE American: PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 2, 2025 and October 31, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 3, 2026.

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Picard Medical, Inc. (NYSE American: PMI) between September 2, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased Picard Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.